Way more biologic stability, a lot less protein
Formulation scientists are expected to do a lot more with less—more constructs, higher concentrations, less volume. Novel antibody structures and ADCs present a different challenge for development.
Live Webinar: Thursday, December 10, 2015 at 2 pm EST | 11 am PST
|
|
ON DEMAND WEBCASTS |
Automated De Novo Identification and Profiling of Disulfide Bonds in Biotherapeutics Including Analysis of Disulfide Bond Scrambling in Monoclonal Antibodies
Recorded: Tuesday, November 3, 2015
|
Monoclonal Antibody Purification by Protein A Affinity and Hydroxyapatite Mixed Mode: Multi-Column Continuous Chromatography
Recorded: Wednesday, October 7 2015
|
Built for Biopharma: State-of-the-Art UHPLC for Characterizing Biotherapeutics
Recorded: Thursday, September 24, 2015
|
Controlling Contamination in Biopharmaceutical Manufacturing
Recorded: US | Tuesday, September 15, 2015 & EU | Tuesday, September. 22, 2015
|
|
|